Clinical course of autologous recovery with chromosomal abnormalities after allogeneic hematopoietic stem cell transplantation

on behalf of Transplantation Complication Working Group of the Japan Society for Hematopoietic Cell Transplantation

Research output: Contribution to journalArticle

Abstract

After primary graft failure following allogeneic hematopoietic stem cell transplantation, some patients experience autologous recovery of hematopoiesis without salvage transplantation. However, clinicians occasionally encounter unusual chromosomal abnormalities in recipient cells, not related to the original underlying diseases. In this study, through a survey based on data from the nationwide registry at the Japan Society for Hematopoietic Cell Transplantation, 42 patients were identified as having chromosomal abnormalities after autologous recovery. The complex chromosomal abnormalities were not consistent and randomly changed at each testing. Of the 42 patients, seven experienced disappearance of chromosome abnormalities without any treatment, and the probability was estimated as 17.4% (95% CI: 7.5–30.7%) at the 5-year observation. On the other hand, two patients developed hematologic malignancy at 1447 and 6202 days. Ten patients were alive without relapse or development of hematologic disorders, even though chromosomal abnormalities were continuously detected at a median of 3192 (103–4710) days. In conclusion, chromosomal abnormalities can persist for more than 10 years, and may eventually contribute to hematologic malignancy development in a small fraction of cases. Although oncogenic effects of the chromosomal abnormalities are still unclear, these findings may provide supporting evidence for late occurrence of secondary malignant neoplasms after cancer treatment.

Original languageEnglish
JournalBone Marrow Transplantation
DOIs
Publication statusAccepted/In press - 2019 Jan 1

Fingerprint

Hematopoietic Stem Cell Transplantation
Chromosome Aberrations
Hematologic Neoplasms
Cell Transplantation
Hematopoiesis
Registries
Neoplasms
Japan
Transplantation
Observation
Transplants
Recurrence
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

on behalf of Transplantation Complication Working Group of the Japan Society for Hematopoietic Cell Transplantation (Accepted/In press). Clinical course of autologous recovery with chromosomal abnormalities after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation. https://doi.org/10.1038/s41409-019-0765-0

Clinical course of autologous recovery with chromosomal abnormalities after allogeneic hematopoietic stem cell transplantation. / on behalf of Transplantation Complication Working Group of the Japan Society for Hematopoietic Cell Transplantation.

In: Bone Marrow Transplantation, 01.01.2019.

Research output: Contribution to journalArticle

on behalf of Transplantation Complication Working Group of the Japan Society for Hematopoietic Cell Transplantation. Clinical course of autologous recovery with chromosomal abnormalities after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation. 2019 Jan 1. https://doi.org/10.1038/s41409-019-0765-0
on behalf of Transplantation Complication Working Group of the Japan Society for Hematopoietic Cell Transplantation. / Clinical course of autologous recovery with chromosomal abnormalities after allogeneic hematopoietic stem cell transplantation. In: Bone Marrow Transplantation. 2019.
@article{6f389f28d2474847affed8733de2231e,
title = "Clinical course of autologous recovery with chromosomal abnormalities after allogeneic hematopoietic stem cell transplantation",
abstract = "After primary graft failure following allogeneic hematopoietic stem cell transplantation, some patients experience autologous recovery of hematopoiesis without salvage transplantation. However, clinicians occasionally encounter unusual chromosomal abnormalities in recipient cells, not related to the original underlying diseases. In this study, through a survey based on data from the nationwide registry at the Japan Society for Hematopoietic Cell Transplantation, 42 patients were identified as having chromosomal abnormalities after autologous recovery. The complex chromosomal abnormalities were not consistent and randomly changed at each testing. Of the 42 patients, seven experienced disappearance of chromosome abnormalities without any treatment, and the probability was estimated as 17.4{\%} (95{\%} CI: 7.5–30.7{\%}) at the 5-year observation. On the other hand, two patients developed hematologic malignancy at 1447 and 6202 days. Ten patients were alive without relapse or development of hematologic disorders, even though chromosomal abnormalities were continuously detected at a median of 3192 (103–4710) days. In conclusion, chromosomal abnormalities can persist for more than 10 years, and may eventually contribute to hematologic malignancy development in a small fraction of cases. Although oncogenic effects of the chromosomal abnormalities are still unclear, these findings may provide supporting evidence for late occurrence of secondary malignant neoplasms after cancer treatment.",
author = "{on behalf of Transplantation Complication Working Group of the Japan Society for Hematopoietic Cell Transplantation} and Motohiro Kato and Hideki Nakasone and Nobuaki Nakano and Shigeo Fuji and Akihito Shinohara and Hisayuki Yokoyama and Kazuo Sakashita and Tsukasa Hori and Satoshi Takahashi and Miho Nara and Yoshinobu Kanda and Takehiko Mori and Junko Takita and Hiroshi Kawaguchi and Toshiro Kawakita and Tatsuo Ichinohe and Takahiro Fukuda and Yoshiko Atsuta and Masao Ogata",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41409-019-0765-0",
language = "English",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Clinical course of autologous recovery with chromosomal abnormalities after allogeneic hematopoietic stem cell transplantation

AU - on behalf of Transplantation Complication Working Group of the Japan Society for Hematopoietic Cell Transplantation

AU - Kato, Motohiro

AU - Nakasone, Hideki

AU - Nakano, Nobuaki

AU - Fuji, Shigeo

AU - Shinohara, Akihito

AU - Yokoyama, Hisayuki

AU - Sakashita, Kazuo

AU - Hori, Tsukasa

AU - Takahashi, Satoshi

AU - Nara, Miho

AU - Kanda, Yoshinobu

AU - Mori, Takehiko

AU - Takita, Junko

AU - Kawaguchi, Hiroshi

AU - Kawakita, Toshiro

AU - Ichinohe, Tatsuo

AU - Fukuda, Takahiro

AU - Atsuta, Yoshiko

AU - Ogata, Masao

PY - 2019/1/1

Y1 - 2019/1/1

N2 - After primary graft failure following allogeneic hematopoietic stem cell transplantation, some patients experience autologous recovery of hematopoiesis without salvage transplantation. However, clinicians occasionally encounter unusual chromosomal abnormalities in recipient cells, not related to the original underlying diseases. In this study, through a survey based on data from the nationwide registry at the Japan Society for Hematopoietic Cell Transplantation, 42 patients were identified as having chromosomal abnormalities after autologous recovery. The complex chromosomal abnormalities were not consistent and randomly changed at each testing. Of the 42 patients, seven experienced disappearance of chromosome abnormalities without any treatment, and the probability was estimated as 17.4% (95% CI: 7.5–30.7%) at the 5-year observation. On the other hand, two patients developed hematologic malignancy at 1447 and 6202 days. Ten patients were alive without relapse or development of hematologic disorders, even though chromosomal abnormalities were continuously detected at a median of 3192 (103–4710) days. In conclusion, chromosomal abnormalities can persist for more than 10 years, and may eventually contribute to hematologic malignancy development in a small fraction of cases. Although oncogenic effects of the chromosomal abnormalities are still unclear, these findings may provide supporting evidence for late occurrence of secondary malignant neoplasms after cancer treatment.

AB - After primary graft failure following allogeneic hematopoietic stem cell transplantation, some patients experience autologous recovery of hematopoiesis without salvage transplantation. However, clinicians occasionally encounter unusual chromosomal abnormalities in recipient cells, not related to the original underlying diseases. In this study, through a survey based on data from the nationwide registry at the Japan Society for Hematopoietic Cell Transplantation, 42 patients were identified as having chromosomal abnormalities after autologous recovery. The complex chromosomal abnormalities were not consistent and randomly changed at each testing. Of the 42 patients, seven experienced disappearance of chromosome abnormalities without any treatment, and the probability was estimated as 17.4% (95% CI: 7.5–30.7%) at the 5-year observation. On the other hand, two patients developed hematologic malignancy at 1447 and 6202 days. Ten patients were alive without relapse or development of hematologic disorders, even though chromosomal abnormalities were continuously detected at a median of 3192 (103–4710) days. In conclusion, chromosomal abnormalities can persist for more than 10 years, and may eventually contribute to hematologic malignancy development in a small fraction of cases. Although oncogenic effects of the chromosomal abnormalities are still unclear, these findings may provide supporting evidence for late occurrence of secondary malignant neoplasms after cancer treatment.

UR - http://www.scopus.com/inward/record.url?scp=85076564835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076564835&partnerID=8YFLogxK

U2 - 10.1038/s41409-019-0765-0

DO - 10.1038/s41409-019-0765-0

M3 - Article

C2 - 31819152

AN - SCOPUS:85076564835

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

ER -